April 2010
Volume 51, Issue 13
ARVO Annual Meeting Abstract  |   April 2010
Vitreal Pharmacokinetics of Peptide Transporter Targeted Prodrugs of Ganciclovir in Conscious Animals
Author Affiliations & Notes
  • A. Ray
    Pharmaceutical sciences, university of missouri at kansas city, Kansas city, Missouri
  • S. H. S. Boddu
    Pharmaceutical Sciences, University of Missouri at Kansas City, Kansas City, Missouri
  • A. K. Mitra
    School of Pharmacy, University of Missouri, Kansas City, Missouri
  • Footnotes
    Commercial Relationships  A. Ray, None; S.H.S. Boddu, None; A.K. Mitra, None.
  • Footnotes
    Support  NIH grant R01 EY-09171-12 and R01-EY 10659-10
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 831. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. Ray, S. H. S. Boddu, A. K. Mitra; Vitreal Pharmacokinetics of Peptide Transporter Targeted Prodrugs of Ganciclovir in Conscious Animals. Invest. Ophthalmol. Vis. Sci. 2010;51(13):831.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : The aim of this study is to delineate the vitreal pharmacokinetics of di-peptide monoester prodrugs of ganciclovir (GCV) with conscious rabbit model using ocular microdialysis and to compare with published results from anesthetized model.

Methods: : New Zealand albino male rabbit was selected as the animal model. Conscious animal ocular microdialysis technique with permanently implanted probes was employed to delineate the pharmacokinetics of GCV, L-valine-GCV and dipeptide monoester GCV prodrugs (L-valine-L-valine and L-glycine-L-valine) following intravitreal administration.

Results: : The present work employs conscious model to evaluate vitreal pharmacokinetic parameters and compares the results with previously published data from anesthetized animal, thereby demonstrating the effect of anesthesia on the vitreal disposition of di-peptide prodrugs of GCV. Results have revealed that AUC, Clearance and Clast for all four compounds were significantly altered in a conscious animal relative to the anesthetized model, while MRT was significantly reduced. However, the AUCs of regenerated Val-GCV and GCV from Gly-Val-GCV and Val-Val-GCV were found to be unchanged suggesting higher ocular metabolism in conscious animals.

Conclusions: : This study for the first time delineates the vitreal pharmacokinetics of a GCV prodrug in conscious animals and compares the data with anesthetized animals. Lower vitreal exposure levels were obtained in case of conscious animal model; however the elimination rates were not influenced by anesthesia.FIGURE 1: Vitreous concentration-time profiles of Val-GCV and regenerated ganciclovir (GCV). Mean values are represented (n=4).Vitreous concentration-time profile of ganciclovir (GCV). Mean values are represented (n=4)FIGURE 2: Vitreous concentration-time profiles of Val-Val-GCV and regenerated ganciclovir (GCV) and Val-GCV. Mean values are represented (n=4).

Keywords: antiviral drugs • vitreous • AIDS/HIV 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.